ASCO Annual Meeting | Conference

TTFields Plus BSC Prolongs Time to Intracranial Progression in NSCLC Brain Metastases

June 4th 2024

TTFields therapy plus best supportive care increased time to first intracranial progression by 10.6 months in patients with NSCLC brain metastases.

Dr Eads on Nivolumab Plus Neoadjuvant Chemoradiation in Esophageal/GEJ Cancer

June 4th 2024

Jennifer R. Eads, MD, discusses neoadjuvant pCR rates with the addition of nivolumab to neoadjuvant chemoradiation in esophageal/GEJ cancer.

Dr Classe on Lymphadenectomy Omission in Advanced Epithelial Ovarian Cancer

June 4th 2024

Jean-Marc Classe, MD, PhD, discusses lymphadenectomy omission following cytoreductive surgery after chemotherapy in advanced epithelial ovarian cancer.

Frontline Petosemtamab Doublet Elicits Responses in Recurrent/Metastatic HNSCC

June 4th 2024

Petosemtamab paired with pembrolizumab had early clinical efficacy when used as first-line treatment in select head and neck squamous cell carcinoma

Nivolumab Plus Ipilimumab and Chemo Maintains OS Benefit in NSCLC

June 4th 2024

Nivolumab plus ipilimumab and chemotherapy elicited a durable, long-term survival benefit vs chemotherapy alone in metastatic NSCLC.

Dr McGregor on the DAD-IO Trial in Treatment-Naive Metastatic Urothelial Carcinoma

June 4th 2024

Bradley McGregor, MD, discusses the DAD-IO trial of sacituzumab govitecan, enfortumab vedotin, and pembrolizumab in metastatic urothelial cancer.

D-VRd Boosts MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

June 4th 2024

Daratumumab plus VRd increased rates of MRD negativity in newly diagnosed, transplant-eligible multiple myeloma.

Avelumab Plus Cisplatin-Based Chemotherapy Yields High EFS and OS Rates in MIUC

June 4th 2024

The addition of avelumab to cisplatin-based chemotherapy led to high event-free survival and overall survival rates in patients with muscle-invasive urothelial carcinoma.

Isa-VRd Prolongs PFS in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

June 4th 2024

Isatuximab plus VRd produced a statistically significant improvement in PFS vs VRd in newly diagnosed, transplant-ineligible multiple myeloma.

Dostarlimab 2 for 2: Snagging 100% Clinical CR in dMMR Locally Advanced Rectal Cancer

June 3rd 2024

In a phase 2 trial, all 42 patients with locally advanced mismatch repair–deficient rectal cancer achieved clinical complete response with dostarlimab.

Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC

June 3rd 2024

Neoadjuvant nivolumab/chemotherapy, followed by surgery and adjuvant nivolumab, significantly improved EFS in stage III N2 and stage III non-N2 NSCLC.

Dato-DXd Demonstrates Intracranial Activity in Advanced NSCLC With/Without Brain Metastases

June 3rd 2024

Datopotamab deruxtecan demonstrated comparable intracranial activity and safety in pretreated patients with NSCLC with or without brain metastases.

Dr Facon on the Efficacy of Isa-VRd in Newly Diagnosed Multiple Myeloma

June 3rd 2024

Thierry Facon, MD, discusses findings from the phase 3 IMROZ trial investigating Isa-VRd in patients with newly diagnosed multiple myeloma.

Dr Kalinsky on Abemaciclib/Fulvestrant in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

June 3rd 2024

Kevin Kalinsky, MD, MS, on abemaciclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after progression on a CDK4/6 inhibitor and endocrine therapy.

Updated CheckMate 816 Data Reinforce Neoadjuvant Nivolumab/Chemo as a SOC for Resectable NSCLC

June 3rd 2024

Neoadjuvant nivolumab with chemotherapy led to durable EFS benefit and a trend toward improved OS vs chemotherapy alone in patients with resectable NSCLC.

DFS, OS Benefit Maintained With Adjuvant Atezolizumab vs BSC in Stage II/IIIA NSCLC

June 3rd 2024

Long-term DFS and OS outcomes with adjuvant atezolizumab in stage II to IIIA NSCLC were consistent with prior data from the IMpower010 trial.

KIM-1 Shows Prognostic and Predictive Value With Adjuvant Atezolizumab in RCC

June 3rd 2024

Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease (MRD), disease recurrence, and benefit from adjuvant atezolizumab (Tecentriq) in patients with renal cell carcinoma (RCC) at increased risk of recurrence.

Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC

June 3rd 2024

Lenvatinib plus pembrolizumab displayed a superior clinical benefit vs sunitinib irrespective of patient biomarker subtype in advanced clear cell RCC.

CRS, ICANS Incidence Reduced to Zero Following Tocilizumab, Teclistamab Administration in R/R Multiple Myeloma

June 3rd 2024

Tocilizumab plus teclistamab step-up dosing showed efficacy and a mainly mild safety profile in patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin Plus BVd Produces PROs Comparable to DVd in Relapsed/Refractory Multiple Myeloma

June 3rd 2024

Treatment with BVd elicited PROs comparable with those who were treated with DVd in relapsed/refractory multiple myeloma.